At what enterprise value was LONZA CHI acquired in 2026?

During the acquisition of LONZA CHI by LONE STAR FUNDS in 2026, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b CHF. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of LONZA CHI when it was acquired by LONE STAR FUNDS?

The estimated EV/EBITDA multiple for LONZA CHI is in the range of 5x - 12x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was LONZA CHI acquired by LONE STAR FUNDS?

LONZA CHI was acquired by LONE STAR FUNDS in 2026.

What was the revenue of LONZA CHI at the time of the deal?

The revenue of LONZA CHI at the time of the deal is estimated to be in the range of 750M - 1.3b CHF. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of LONZA CHI during the acquisition?

LONZA CHI's EBITDA is estimated to be in the range of 250M - 500M CHF. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the LONZA CHI acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the LONZA CHI deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.lonestarfunds.com/lone-star-funds-announces-agreement-to-acquire-the-capsules-health-ingredients-division-of-lonza-group-ag/

← DATABASE

Home Database Healthcare & PharmaLONZA CHI

03/2026

LONZA CHI acquired by LONE STAR FUNDS

SWITZERLAND Life Sciences / Pharma & Biotech / CDMO EV 1b - 4b CHF

Context

Lone Star Funds has entered into a definitive agreement to acquire a majority stake in Lonza Group’s Capsules & Health Ingredients (CHI) division. Lonza will retain a 40% equity position in the newly independent business, ensuring industrial continuity and shared upside in the future growth of the platform. The strategic rationale for Lonza is the completion of its long-term transformation into a "pure-play" CDMO (Contract Development and Manufacturing Organization). For CHI, the transition to a standalone entity under Lone Star’s control is designed to enhance its strategic agility and provide the dedicated capital necessary to accelerate innovation in plant-based capsules and nutritional ingredients. The sale process, which began in late 2024, was advised by Bank of America and Centerview Partners. This carve-out follows several other Lonza divestitures, including its Personalized Medicines and MODA software businesses.

LONZA CHI, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Lonza CHI (Capsules & Health Ingredients) is a global leader in the production of hard capsules and dosage form solutions for the pharmaceutical and nutraceutical industries. The business operates across three integrated segments: Hard Empty Capsules (gelatin and plant-based), Dosage Form Solutions, and Health Ingredients (science-backed nutrition for joint health and energy). With a manufacturing footprint spanning the Americas, Europe, and Asia Pacific, CHI is recognized for its high-quality technical capabilities and established relationships with blue-chip global customers. The entity acts as a critical supply chain partner, offering end-to-end development platforms from raw ingredients to finished dosage forms, benefiting from structural growth trends in the global health and active lifestyle markets.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (CHF)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
04/2026	OURY MEDICAL	CÉFIMÉCA	FRANCE	Life Sciences	The acquisition of Céfiméca by Oury Medical represents a strategic consolidation within the French orthopedic and spinal medical device market. This transaction is the fifth build-up operation completed by Oury Medical in three years, following a platform strategy initiated by its lead investors
04/2026	FOR TALENTS / UI INVESTISSEMENT / GENEO	NEFTYS PHARMA	FRANCE	Life Sciences	In a structured minority growth equity transaction, specialized family capital investment firm For Talents has acquired a minority stake in Neftys Pharma. This strategic operation is executed alongside incumbent financial sponsors UI Investissement and GENEO Capital Entrepreneur, who are rolling over their investments after an initial four-year holding period
03/2026	RESONETICS	RESOLUTION MEDICAL	UNITED STATES	Life Sciences	The acquisition of Resolution Medical by Resonetics signifies a major step in the group’s expansion toward a comprehensive, full-lifecycle service model. The strategic rationale for this transaction centers on an "integrated-platform" maneuver, merging the target’s technical operational depth in biosimulation and cleanroom assembly with the acquirer’s established scale in laser-based component manufacturing and battery systems
03/2026	DEUTSCHE BETEILIGUNGS (DBAG)	HIPP TECHNOLOGY GROUP	GERMANY	Life Sciences	Deutsche Beteiligungs AG (DBAG) has entered into a definitive agreement to acquire a majority stake in Hipp Technology Group, marking a significant entry into the medical contract manufacturing space. The transaction involves the acquisition of the majority interest previously held by the Swiss investment firm Endura Capital, with the financing provided by DBAG Fund VIII
03/2026	SIPAREX	WINNCARE	FRANCE	Life Sciences	Siparex has reaffirmed its commitment to Winncare by leading a quaternary LBO to retain control of the medical device manufacturer. This transaction allows Siparex, which originally acquired the company in 2021 via its ETI 5 fund, to extend the maturity of its investment while slightly increasing its ownership stake alongside the management team led by President Laurent Faugères
02/2026	VIVO CAPITAL	DUTSCHER	FRANCE	Life Sciences	Vivo Capital acquired a majority stake in Dutscher from LBO France. LBO France had acquired the asset in July 2020 from Five Arrows (Rothschild) for an enterprise value of EUR100-150M (investing EUR60M in equity)
02/2026	NORD HOLDING	HALLMARQ VETERINARY IMAGING	UNITED KINGDOM	Life Sciences	NORD Holding have acquired Hallmarq Veterinary Imaging from August Equity to merge it with German-based OR Technology. The transaction establishes a new, globally active imaging technology holding company in the veterinary sector
02/2026	IMA GROUP	PROSYS	IRELAND	Life Sciences	IMA Group acquired a majority stake in ProSys Sampling Systems Limited from its co-founder and Treysa Limited. The transaction is a core component of IMA's international growth strategy, aiming to strengthen its "IMA Life" division by integrating specialized containment and sampling expertise
02/2026	CIMG	DAREN TECHNOLOGY	CHINA	Life Sciences	CIMG, through its subsidiary DZR, signed an agreement to acquire 100% of Daren Technology for approximately $40M in stock. The transaction features a highly structured Phased Payment consideration (6%, 14%, 28%, and 52%) released over 3
01/2026	YOTTA CAPITAL	VILLARD	FRANCE	Life Sciences	Yotta Capital Partners led a majority buyout of Villard, succeeding the previous sponsorless structure held by CEO. The transaction values the company on a solid growth trajectory, with the management team and historical regional partners reinvesting in the new pool

REFERENCES

Valuation range: EV 1b - 4b CHF

Revenue range: 750M - 1.3b CHF

EBITDA range: 250M - 500M CHF

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LONZA CHI by LONE STAR FUNDS are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Acquirer: lone star funds